As the need for Covid testing has waned, small-cap UK testing companies have been left fighting battles with the DHSC and struggling to remain relevant to investors, through continued innovation or pivots to related sectors. Amid a broader risk-off climate, many of their investors, still holding onto greatly depreciated shares, are left weighing their options.
Indirect Tekcapital holding MicroSalt has executed the first bulk B2B order of its low-sodium salt in the US, with the product now available in over 3,000 retail stores in the US, up from 2400 QoQ. MicroSalt also mentioned a potential future listing in London.
- Worse to come for food price rises, warns industry - Flight cancellation plan aims to ease summer chaos - UK banks’ profits surge past French rivals for first time since before Brexit vote 3 to 5 stories featured in today's podcast